185 related articles for article (PubMed ID: 23284638)
21. Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Hu DX; Tang WL; Zhang Y; Yang H; Wang W; Agama K; Pommier Y; An LK
J Med Chem; 2021 Jun; 64(11):7617-7629. PubMed ID: 34008967
[TBL] [Abstract][Full Text] [Related]
22. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
23. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.
Nguyen TX; Abdelmalak M; Marchand C; Agama K; Pommier Y; Cushman M
J Med Chem; 2015 Apr; 58(7):3188-208. PubMed ID: 25811317
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
27. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
29. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.
Antony S; Kohlhagen G; Agama K; Jayaraman M; Cao S; Durrani FA; Rustum YM; Cushman M; Pommier Y
Mol Pharmacol; 2005 Feb; 67(2):523-30. PubMed ID: 15531731
[TBL] [Abstract][Full Text] [Related]
30. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
31. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.
Xu Y; Her C
Biomolecules; 2015 Jul; 5(3):1652-70. PubMed ID: 26287259
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Jing CB; Fu C; Prutsch N; Wang M; He S; Look AT
Leukemia; 2020 Nov; 34(11):2992-3006. PubMed ID: 32572188
[TBL] [Abstract][Full Text] [Related]
34. Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A; Pommier Y
Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
[TBL] [Abstract][Full Text] [Related]
35. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
[TBL] [Abstract][Full Text] [Related]
37. Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
Lee YC; Lee CH; Tsai HP; An HW; Lee CM; Wu JC; Chen CS; Huang SH; Hwang J; Cheng KT; Leiw PL; Chen CL; Lin CM
PLoS One; 2015; 10(7):e0132579. PubMed ID: 26207989
[TBL] [Abstract][Full Text] [Related]
38. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor.
Dyrkheeva NS; Malakhova AA; Zakharenko AL; Okorokova LS; Shtokalo DN; Pavlova SV; Medvedev SP; Zakian SM; Nushtaeva AA; Tupikin AE; Kabilov MR; Khodyreva SN; Luzina OA; Salakhutdinov NF; Lavrik OI
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982223
[TBL] [Abstract][Full Text] [Related]
40. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
